Invex Therapeutics (ASX:IXC) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 05, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Invex Therapeutics's float shares is 0.00 Mil. Invex Therapeutics's total shares outstanding is 75.15 Mil. Invex Therapeutics's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Invex Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Invex Therapeutics's Institutional Ownership is 0.01%.

Invex Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Invex Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	75.15
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics (ASX:IXC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.